The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The price of Standard BioTools Inc (NASDAQ: LAB) closed at $1.90 in the last session, up 5.56% from day before closing price of $1.80. In other words, the price has increased by $5.56 from its previous closing price. On the day, 0.95 million shares were traded. LAB stock price reached its highest trading level at $1.905 during the session, while it also had its lowest trading level at $1.79.
Ratios:
We take a closer look at LAB’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 3.53 and its Current Ratio is at 3.88. In the meantime, Its Debt-to-Equity ratio is 0.18 whereas as Long-Term Debt/Eq ratio is at 0.06.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, TD Cowen on April 16, 2024, initiated with a Buy rating and assigned the stock a target price of $3.50.
On April 04, 2024, Jefferies started tracking the stock assigning a Buy rating and target price of $3.25.
On July 12, 2023, KeyBanc Capital Markets started tracking the stock assigning a Overweight rating and target price of $4.KeyBanc Capital Markets initiated its Overweight rating on July 12, 2023, with a $4 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Sep 09 ’24 when Taich Adam bought 45,851 shares for $2.00 per share.
Casdin Partners Master Fund, L bought 250,000 shares of LAB for $546,750 on Aug 27 ’24. The Director now owns 54,025,821 shares after completing the transaction at $2.19 per share. On Aug 23 ’24, another insider, Casdin Partners Master Fund, L, who serves as the Director of the company, bought 292,100 shares for $2.13 each. As a result, the insider paid 620,975 and bolstered with 53,625,821 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, LAB now has a Market Capitalization of 705192576 and an Enterprise Value of 228835808. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.17 while its Price-to-Book (P/B) ratio in mrq is 1.38. Its current Enterprise Value per Revenue stands at 1.679 whereas that against EBITDA is -2.194.
Stock Price History:
Over the past 52 weeks, LAB has reached a high of $3.04, while it has fallen to a 52-week low of $1.21. The 50-Day Moving Average of the stock is -0.76%, while the 200-Day Moving Average is calculated to be -15.20%.
Shares Statistics:
According to the various share statistics, LAB traded on average about 2.10M shares per day over the past 3-months and 1096530 shares per day over the past 10 days. A total of 371.15M shares are outstanding, with a floating share count of 359.12M. Insiders hold about 3.24% of the company’s shares, while institutions hold 72.52% stake in the company. Shares short for LAB as of 1727654400 were 21293767 with a Short Ratio of 10.16, compared to 1724976000 on 22232330. Therefore, it implies a Short% of Shares Outstanding of 21293767 and a Short% of Float of 11.82.
